Mark R. Barakat

1 week ago | ophthalmologytimes.com | Dilsher S. Dhoot |Mark R. Barakat |Martin Harp |Hattie Hayes

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervalsEditor's note: The below transcript has been lightly edited for clarity. Hi, I'm here at ARVO 2025, and I'm presenting a poster for EYLEA HD and looking specifically at the PHOTON data. This is a post-hoc analysis.